AstraZeneca plc (GB:AZN) has released an update.
AstraZeneca’s SUPERNOVA Phase III trial has yielded positive results, showing that its investigational long-acting antibody, sipavibart, significantly reduces symptomatic COVID-19 in immunocompromised patients. This large global trial provides the first efficacy data for a COVID-19 antibody against recent SARS-CoV-2 variants in a group that includes blood cancer patients and organ transplant recipients, among others. With the immunocompromised constituting a substantial portion of severe COVID-19 cases, sipavibart offers a promising preventive treatment for this vulnerable population.
For further insights into GB:AZN stock, check out TipRanks’ Stock Analysis page.
